Details of the Drug Combination

General Information of Drug Combination (ID: DCN2MPA)

Drug Combination Name
Emtricitabine Didanosine
Indication
Disease Entry Status REF
HIV Infections Phase 4 [1]
Component Drugs Emtricitabine   DMBMUWZ Didanosine   DMI2QPE
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Emtricitabine
Disease Entry ICD 11 Status REF
Hepatitis virus infection 1E50-1E51 Approved [2]
Human immunodeficiency virus infection 1C62 Approved [2]
Hepatitis B virus infection 1E51.0 Phase 3 [3]
Emtricitabine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human immunodeficiency virus Reverse transcriptase (HIV RT) TT84ETX POL_HV1B1 Modulator [2]
------------------------------------------------------------------------------------
Emtricitabine Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug and toxin extrusion protein 1 (SLC47A1) DTZGT0P S47A1_HUMAN Substrate [5]
------------------------------------------------------------------------------------
Emtricitabine Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
E3 ubiquitin-protein ligase parkin (PRKN) OTJBN41W PRKN_HUMAN Decreases Expression [6]
Albumin (ALB) OTVMM513 ALBU_HUMAN Affects Binding [7]
Deoxycytidine kinase (DCK) OTW8HLZC DCK_HUMAN Affects Binding [8]
------------------------------------------------------------------------------------
Indication(s) of Didanosine
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [4]
Didanosine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human immunodeficiency virus Reverse transcriptase (HIV RT) TT84ETX POL_HV1B1 Inhibitor [9]
------------------------------------------------------------------------------------
Didanosine Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Concentrative nucleoside transporter 2 (SLC28A2) DT82KPY S28A2_HUMAN Substrate [10]
------------------------------------------------------------------------------------
Didanosine Interacts with 10 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2E1 (CYP2E1) OTHQ17JG CP2E1_HUMAN Increases ADR [11]
Cytochrome c oxidase subunit 2 (COX2) OTTMVBJJ COX2_HUMAN Decreases Expression [12]
Albumin (ALB) OTVMM513 ALBU_HUMAN Affects Binding [7]
Antileukoproteinase (SLPI) OTUNFUU8 SLPI_HUMAN Increases Expression [13]
Interleukin-24 (IL24) OT4VUWH1 IL24_HUMAN Decreases Expression [13]
DNA-directed RNA polymerase, mitochondrial (POLRMT) OT5Q8ZUJ RPOM_HUMAN Increases ADR [11]
L-serine dehydratase/L-threonine deaminase (SDS) OT5WTJ2M SDHL_HUMAN Increases ADR [11]
Equilibrative nucleoside transporter 3 (SLC29A3) OTGLX8XU S29A3_HUMAN Affects Transport [14]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases ADR [11]
Cytochrome c oxidase subunit 4 isoform 1, mitochondrial (COX4I1) OTU0FC24 COX41_HUMAN Increases ADR [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DOT(s)

References

1 ClinicalTrials.gov (NCT00084136) Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
2 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
3 Clinical pipeline report, company report or official report of Gilead (2011).
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4833).
5 Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters. Xenobiotica. 2017 Jan;47(1):77-85.
6 Chronic Nucleoside Reverse Transcriptase Inhibitors Disrupt Mitochondrial Homeostasis and Promote Premature Endothelial Senescence. Toxicol Sci. 2019 Dec 1;172(2):445-456. doi: 10.1093/toxsci/kfz203.
7 Binding of anti-HIV drugs to human serum albumin. IUBMB Life. 2004 Oct;56(10):609-14. doi: 10.1080/15216540400016286.
8 Nonenantioselectivity property of human deoxycytidine kinase explained by structures of the enzyme in complex with L- and D-nucleosides. J Med Chem. 2007 Jun 28;50(13):3004-14. doi: 10.1021/jm0700215. Epub 2007 May 27.
9 The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):298-304.
10 Clinical Nephrotoxins: Renal Injury from Drugs and Chemicals.
11 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
12 In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother. 2006 Nov;50(11):3824-32. doi: 10.1128/AAC.00437-06. Epub 2006 Aug 28.
13 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
14 Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G910-22. doi: 10.1152/ajpgi.90672.2008. Epub 2009 Jan 22.